Merck Stock Dips 1.27% with $907M Trading Volume Ranking 92nd as it Partners with Antengene for Cancer Treatment

On May 21, 2025, Merck & Co., Inc. (MRK) experienced a decline of 1.27% in its stock price, with a trading volume of $907 million, placing it at the 92nd position in terms of trading volume for the day.

Merck & Co., Inc. has recently entered into a global clinical collaboration with Antengene Corporation Limited to evaluate the combination of ATG-022, an antibody-drug conjugate targeting CLDN18.2, with KEYTRUDA, Merck's anti-PD-1 therapy. This collaboration aims to explore the potential of this combination in treating various types of cancer, leveraging the strengths of both companies' innovative therapies.

This strategic partnership is expected to enhance Merck's oncology portfolio and potentially drive future growth, as it continues to focus on developing and delivering innovative treatments for cancer patients. The collaboration with Antengene is part of Merck's broader strategy to advance its pipeline through strategic partnerships and collaborations with other biopharmaceutical companies.